56 related articles for article (PubMed ID: 12040389)
21. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
22. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
23. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
[TBL] [Abstract][Full Text] [Related]
24. Genetic stability of recombinant MVA-BN.
Timm A; Enzinger C; Felder E; Chaplin P
Vaccine; 2006 May; 24(21):4618-21. PubMed ID: 16157428
[TBL] [Abstract][Full Text] [Related]
25. Modified vaccinia virus Ankara as a vector for suicide gene therapy.
Erbs P; Findeli A; Kintz J; Cordier P; Hoffmann C; Geist M; Balloul JM
Cancer Gene Ther; 2008 Jan; 15(1):18-28. PubMed ID: 17992203
[TBL] [Abstract][Full Text] [Related]
26. Construction of cDNA libraries in vaccinia virus.
Smith ES; Shi S; Zauderer M
Methods Mol Biol; 2004; 269():65-76. PubMed ID: 15114008
[TBL] [Abstract][Full Text] [Related]
27. Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.
Hansen H; Okeke MI; Nilssen O; Traavik T
Vaccine; 2004 Dec; 23(4):499-506. PubMed ID: 15530698
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
29. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
30. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
Olszewska W; Suezer Y; Sutter G; Openshaw PJ
Vaccine; 2004 Nov; 23(2):215-21. PubMed ID: 15531040
[TBL] [Abstract][Full Text] [Related]
31. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
32. [Construction of recombinant vaccinia virus expressing HSV-2 gD gene as live recombinant vaccine strain].
Yan H; Rong M; Ruan L; Hou Y; He N; Zhu J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):16-20. PubMed ID: 15619895
[TBL] [Abstract][Full Text] [Related]
33. Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.
Albrecht M; Suezer Y; Staib C; Sutter G; Vieths S; Reese G
J Gene Med; 2008 Dec; 10(12):1324-33. PubMed ID: 18816482
[TBL] [Abstract][Full Text] [Related]
34. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Recombinant MVA Selection Methods Based on F13L, D4R and K1L Genes.
Antoshkina IV; Glazkova DV; Urusov FA; Bogoslovskaya EV; Shipulin GA
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336935
[TBL] [Abstract][Full Text] [Related]
36. MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease.
Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B
bioRxiv; 2021 Jan; ():. PubMed ID: 33442693
[TBL] [Abstract][Full Text] [Related]
37. Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting.
Boselli D; Panigada M; Di Terlizzi S; Romanò M; Canonico E; Villa C; Minici C; van Anken E; Soprana E; Siccardi AG
J Transl Med; 2023 Jul; 21(1):495. PubMed ID: 37482614
[TBL] [Abstract][Full Text] [Related]
38. Construction of FWPV Chimaeric MVA.
Buttigieg KR; Skinner MA
Bio Protoc; 2015 Jan; 5(1):. PubMed ID: 29082275
[TBL] [Abstract][Full Text] [Related]
39. Erratum for Sivan et al., "Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L
Sivan G; Ormanoglu P; Buehler EC; Martin SE; Moss B
mBio; 2017 Oct; 8(5):. PubMed ID: 29089434
[No Abstract] [Full Text] [Related]
40. High Frequency of Homologous Recombination in the Genome of Modified Vaccinia Virus Ankara Strain (MVA).
Zhu LX; Xie YH; Li GD; Wang Y
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2001; 33(5):497-503. PubMed ID: 12040389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
